Table 1.
PDX models developed by European Network of Individual Treatment in Endometrial Cancer (ENITEC) consortium members.
| Research Centre | Type of Sample | Type of PDX | Tissue | Engraftment Rate & Time | Mouse Strain | Number Models | Type of Models | Preclinical Drug Tested | |
|---|---|---|---|---|---|---|---|---|---|
| IDIBELL-ICO | Primary tumor, metastases | orthotopic | small tissue fragment | 75–90% | 1–5 months | Athymic nude | 64 | 60%EEC; 10%PS; 20%CS; 3%CC; 7%other types | Sorafenib, Chloroquine (61) |
| VHIR | Primary tumor, metastases, recurrences | heterotopic (s.c) | 5–10 mm3 tissue fragment | 60–80% | 2–3 months | Athymic nude | 40 | 43%EEC; 32%PS; 10%CS; 2.5%CC; 5%undifferentiated 7.5%other types | Carboplatin Paclitaxel, Palbociclib (60) |
| KUL | Primary tumor, metastases, recurrences | heterotopic (s.c) | 8–10 mm3 tissue fragment | 100% | 3–5 months | Athymic nude | 15 | 46%EEC; 13%PS; 13%CS; 7%undifferentiated 21%other types | Carboplatin, NVP-BEZ235, AZD 6244 (33) |
| HUHB | Primary tumor, metastases | orthotopic | Cell suspension | 25–100% | 3–13 months | NSG | 5 | 60%EEC; 20%PS; 20%undifferentiated | |
IDIBELL-ICO: Institute of biomedical research from Bellvitge–Institute Catalan of Oncology; VHIR: Vall d’Hebron Institute of Research; KUL: Katholieke Universiteit Leuven; HUHB: Haukeland University Hospital; EEC: Endometrioid endometrial cancer; PS: Papillary serous carcinoma; CS: Carcinosarcoma; CC: Clear cell carcinoma; s.c: Subcutaneous.